RTP Mobile Logo

This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gastrointestinal (GI) cancers.

Given the prevalent nature of the disease, extensive resources are allocated to colorectal cancer research and education. Interestingly, however, although individually less frequently encountered, the collection of other noncolorectal GI cancers accounts for more per annum cancer-related deaths than those attributed to tumors of the colon and rectum combined. Among this collection of distinct tumor types, a few areas in particular — namely gastric, pancreatic and hepatocellular cancer — have witnessed several recent advances that have altered or have the potential to drastically alter current treatment considerations and approaches.

These proceedings from a CME symposium during the 2019 ASCO Annual Meeting explore the most significant therapeutic advances in the field of GI cancers by using the perspectives of leading experts on challenging cases and questions submitted by clinicians in the community to frame a relevant discussion of how this information has aided in the refinement of current routine clinical practice and ongoing research. This CME activity will help medical oncologists and other allied healthcare professionals find answers to the individualized questions and concerns that they frequently encounter and in turn provide high-quality cancer care.


  • Develop a long-term care plan for individuals diagnosed with metastatic colorectal cancer, considering the patient’s biomarker profile, tumor location, prior systemic therapy, symptomatology, performance status and personal goals of treatment.
  • Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to optimize the selection and sequence of systemic therapy for locally advanced or metastatic gastroesophageal cancers.
  • Consider age, performance status and other clinical and logistical factors in the selection of systemic therapy for patients with localized, locally advanced or metastatic pancreatic adenocarcinoma.
  • Recall available clinical trial data with approved and investigational systemic interventions, and where appropriate, apply this information to the current clinical care of patients with locally advanced or metastatic hepatocellular carcinoma.
  • Appraise the rationale for and clinical data with commercially available and developmental immune checkpoint inhibitors in the treatment of GI cancers.
  • Counsel appropriately selected patients with GI cancers about participation in ongoing clinical trials evaluating other novel therapeutic agents and strategies.

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOGastrointestinal19/CME.

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Professor Dirk Arnold, MD, PhD
Asklepios Tumorzentrum Hamburg
AK Altona
Hamburg, Germany

No relevant conflicts of interest to disclose.

Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center
Vice-Chair and Section Lead, Division of Medical Oncology
Medical Director, Cancer Clinical Research Office
Senior Associate Consultant
Mayo Clinic
Phoenix, Arizona

Advisory Committee: Amgen Inc, Immuneering Corporation, Imugene; Consulting Agreements: AbbVie Inc, Array BioPharma Inc, Bayer HealthCare Pharmaceuticals; Contracted Research: Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc, Bristol-Myers Squibb Company, Genentech, Ipsen Biopharmaceuticals Inc, Novartis; Data and Safety Monitoring Board/Committee: ARMO BioSciences, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Merck, SillaJen.

Joseph Chao, MD
Assistant Clinical Professor
Department of Medical Oncology and Therapeutics Research
Gastrointestinal Cancer Program
City of Hope Comprehensive Cancer Center
Duarte, California

Advisory Committee: Daiichi Sankyo Inc, Merck, Taiho Oncology Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boston Biomedical Inc, Foundation Medicine, Lilly; Contracted Research: Merck, Novonco Therapeutics Inc; Speakers Bureau: Merck.

Anthony El-Khoueiry, MD
Associate Professor of Clinical Medicine
Medical Director of Clinical Investigations Support Office
Phase I Program Director
USC Norris Comprehensive Cancer Center
Los Angeles, California

Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, CytomX Therapeutics, Eisai Inc, EMD Serono Inc, Exelixis Inc, Merck, Pieris Pharmaceuticals Inc; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company; Contracted Research: Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP.

Richard S Finn, MD
Professor of Clinical Medicine
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Director, Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, Genentech, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: Bristol-Myers Squibb Company, Eisai Inc, Genentech, Merck, Pfizer Inc, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.

Yelena Y Janjigian, MD
Chief, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Advisory Committee: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Imugene, Lilly, Merck, Merck Serono, MJH Associates Inc, Pfizer Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech, Lilly, Merck, Roche Laboratories Inc.

Scott Kopetz, MD, PhD
Associate Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Agreements: Amgen Inc, Bayer HealthCare Pharmaceuticals, Genentech.

Eileen M O’Reilly, MD
Winthrop Rockefeller Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary/Neuroendocrine Cancers
Gastrointestinal Oncology Service
Associate Director
David M Rubenstein Center for Pancreatic Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Consulting Agreements: Aptus Pharma, BioLineRx, Bristol-Myers Squibb Company, Celgene Corporation, CytomX Therapeutics, Gilead Sciences Inc, Halozyme Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, NewLink Genetics, Pfizer Inc, PharmaCyte Biotech, Pharmacyclics LLC, an AbbVie Company, Pieris Pharmaceuticals Inc, Sanofi Genzyme, Silenseed Ltd, Sobi, Targovax, twoXAR; Contracted Research: Acta Biológica, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Halozyme Inc, MabVax Therapeutics Inc, OncoQuest Inc, Roche Laboratories Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc and Tolero Pharmaceuticals, Celgene Corporation, Eisai Inc, Exelixis Inc, Genentech, Ipsen Biopharmaceuticals Inc, Lilly, Merck and Taiho Oncology Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: July 2019
Expiration date: July 2020

After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.